secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2023-05-03T23:59:59+00:00
Accession:  0001628280-23-015206
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vanda Q1 2023 revenue $62.5M (+4% YoY); net income $3.3M vs loss
----------------------------------------------------------------

- Net product sales: HETLIOZ $39.6M (+7% YoY), Fanapt $22.9M (-1% YoY).
- Diluted EPS $0.06 vs ($0.11) in prior year; cash $501.5M (+15% YoY).
- Expects sNDA for Fanapt in bipolar I disorder and NDA for tradipitant in gastroparesis in Q2 2023.
- At-risk generic HETLIOZ launch in U.S. likely to cause significant future sales decline; no 2023 guidance provided.
- Awaiting Federal Circuit ruling on HETLIOZ patent appeal; won FOIA lawsuit against FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000162828023015206/0001628280-23-015206-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000162828023015206/vnda-20230503.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-015206

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer